EUVIMEDEUVIMED entdecken
Crossref

Impact of sex on prognosis in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitors

Yuki Nemoto, Hiroki Ishihara, Kazutaka Nakamura, Hidekazu Tachibana, Hironori Fukuda, Kazuhiko Yoshida, Hirohito Kobayashi, Junpei Iizuka, Hiroaki Shimmura, Yasunobu Hashimoto, Tsunenori Kondo, Toshio Takagi

Japanese Journal of Clinical Oncology · 2023

DOI: 10.1093/jjco/hyad025 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Japanese Journal of Clinical Oncology, 2023. Verfasst von Yuki Nemoto und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Tokyo Women's Medical University Adachi Medical Center, Tokyo, Japan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Prognostic impact of sex in patients with malignancies treated with immune checkpoint inhibitors has been intensively discussed but remains unclear, especially in advanced renal cell carcinoma.

Methods

We retrospectively evaluated a total of 184 patients with advanced renal cell carcinoma treated with either nivolumab plus ipilimumab combined treatment as first-line therapy (n = 73) or nivolumab as later-line therapy (n = 111) at our affiliated institutions. Progression-free survival, overall survival and objective response rate as well as adverse event profile were compared between sexes.

Results

Of the total 184 patients, 48 (26%) were female. Female patients had a significantly shorter progression-free survival than male patients (median: 3.8 vs. 8.3 months, P = 0.0005), but overall survival (median: 39.2 vs. 45.1 months, P = 0.283) and objective response rate (29% vs. 42%, P = 0.119) were not different between them. Similar findings were observed when analyzing within each treatment; in both patient groups treated with nivolumab plus ipilimumab combined therapy and nivolumab monotherapy, progression-free survival was significantly shorter in female than in male patients (P = 0.007, P = 0.017), but overall survival (P = 0.914, P = 0.117) and objective response rate (P = 0.109, P = 0.465) were comparable between them. Moreover, in a more restricted cohort consisting of patients with clear-cell renal cell carcinoma, a shorter progression-free survival in female patients was also observed (3.8 vs. 11.0 months, P < 0.0001).

Conclusions

This retrospective study showed that immune checkpoint inhibitors-based treatment for renal cell carcinoma exhibited less marked effects in female than in male patients. Thus, sex may be an important factor for decision-making on systemic therapy as renal cell carcinoma treatment, although further studies are required to validate the present findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsHumansMaleFemaleNivolumabImmune Checkpoint InhibitorsRetrospective StudiesIpilimumabPrognosisAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

cytotoxic T-Lymphocyte Antigen 4immunotherapykidney cancerprogrammed cell death protein 1renal cancer

Substanzen

NivolumabImmune Checkpoint InhibitorsIpilimumab

Autor:innen und Institutionen

  • Department of Urology, Tokyo Women's Medical University Adachi Medical Center, Tokyo, Japan.
  • Department of Urology, Tokyo Women's Medical University, Tokyo, Japan.
  • Department of Urology, Tokiwakai Jyoban Hospital, Fukushima, Japan.
  • Department of Urology, Saiseikai Kazo Hospital, Saitama, Japan.
  • Department of Urology, Saiseikai Kawaguchi General Hospital, Saitama, Japan.

Zitieren

APA

Nemoto, Y., Ishihara, H., Nakamura, K., Tachibana, H., Fukuda, H., Yoshida, K., Kobayashi, H., Iizuka, J., Shimmura, H., Hashimoto, Y., Kondo, T., & Takagi, T. (2023). Impact of sex on prognosis in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitors. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyad025

Vancouver

Nemoto Y, Ishihara H, Nakamura K, Tachibana H, Fukuda H, Yoshida K, et al. Impact of sex on prognosis in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitors. Japanese Journal of Clinical Oncology. 2023. doi:10.1093/jjco/hyad025

BibTeX
@article{Nemoto2023,
  author = {Nemoto, Yuki and Ishihara, Hiroki and Nakamura, Kazutaka and Tachibana, Hidekazu and Fukuda, Hironori and Yoshida, Kazuhiko and Kobayashi, Hirohito and Iizuka, Junpei and Shimmura, Hiroaki and Hashimoto, Yasunobu and Kondo, Tsunenori and Takagi, Toshio},
  title = {Impact of sex on prognosis in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitors},
  journal = {Japanese Journal of Clinical Oncology},
  year = {2023},
  doi = {10.1093/jjco/hyad025}
}
Kostenlos starten →